Vivos Therapeutics exchanged $2,861,270 of principal from its Secured Promissory Note with Streeterville Capital for 11,445,080 shares of common stock at an average price of $0.25 per share on September 2, 2026. The transaction reduced the note's outstanding balance to $3.7 million and increased issued and outstanding shares from approximately 22.2 million to 33.6 million. This issuance represents approximately 34% of the post-transaction common stock base. Vivos Therapeutics operates in the medical device industry, developing implantable neuromodulation devices for sleep-disordered breathing.

Vivos Therapeutics entered into twelve exchange agreements with Streeterville Capital to partition $2,861,270 of its Secured Promissory Note into separate notes. In exchange for the surrender and cancellation of these Partitioned Notes, Vivos agreed to issue up to 11,445,080 shares of common stock at an average price of $0.25 per share. Issuance is subject to a 4.9% beneficial ownership limitation and a sell-down condition requiring Streeterville to dispose of prior issuances before receiving new ones. Following the transaction, the outstanding note balance was reduced to $3.7 million, and total common shares outstanding will increase from approximately 22.2 million to 33.6 million. Vivos Therapeutics develops medical devices for obstructive sleep apnea.

Vivos Therapeutics announced the opening of a new sleep testing and treatment facility in Henderson, Nevada. The company expects this location to more than double its annual production capacity in the area to over $10 million at full capacity. The facility is projected to employ up to 30 personnel, including medical doctors and dentists, as part of the Sleep Centers of Nevada network. This expansion aims to address a surge in patient referrals that has doubled since May 2026. Vivos Therapeutics operates in the medical device and healthcare services industry, focusing on diagnostic and treatment modalities for obstructive sleep apnea.

Vivos Therapeutics, Inc. announced the voluntary resignation of Bradford Amman as Chief Financial Officer and Secretary on July 31, 2026. Amman will serve as a non-executive transition employee for 90 days and an independent contractor advisor for an additional 180 days. His separation agreement includes continued salary during the transition, monthly advisory fees of $13,333, COBRA premium coverage, and equity grants of 250,000 shares and options to purchase 150,000 shares, with full vesting triggered by a completed equity financing of at least $5 million. The Board appointed Roman Franklin as the new Chief Financial Officer effective July 31, 2026. Franklin serves through The CFO Portal, LLC under a Master Services Agreement requiring an annual retainer of $324,000 and an equity award valued at approximately $237,360. Franklin will receive options to purchase 552,000 shares vesting monthly over twelve months. Vivos Therapeutics operates in the medical device industry, developing implantable neuromodulation devices for obstructive sleep apnea.

Vivos Therapeutics, Inc. closed a $2.1 million PIPE offering on June 30, 2026, selling 3,608,496 units consisting of Series A Convertible Preferred Stock and common stock purchase warrants. The offering included $1,000,000 in new cash proceeds and $1,000,000 from the conversion of a previously funded bridge promissory note. The company established a new class of Series A Convertible Preferred Stock with a stated value of $0.456 per share. Vivos Therapeutics, Inc. is a biotechnology company focused on developing medical technology for gastrointestinal health.